

## PRIOR AUTHORIZATION REQUEST FORM

### Medicare Part D- Gilotrif (afatinib)

Phone: 800-728-7947    Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note, any information left blank or illegible may delay the review process.

<b>Patient Name:</b>	<b>Prescriber Name:</b> <b>Supervising Physician:</b>
Member/Subscriber Number:	Fax:                                  Phone:
Date of Birth:	Office Contact:
Group Number:	NPI:                                  State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):

Drug Name and Strength:

Directions / SIG:

**Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.**

Q1. What diagnosis is this drug being prescribed for?

- Metastatic non-small cell lung cancer with EGFR mutation-positive
- Metastatic squamous non-small cell lung cancer
- Other

Q2. If you selected "other" for diagnosis, please provide documentation that use is consistent with a category 2B or higher recommendation per NCCN compendia or guidelines.

Q3. Please provide ICD code(s) for diagnosis

Q4. Is patient a NEW START to treatment with Gilotrif?

- Yes
- No (describe Gilotrif treatment history)

Q5. Is the prescriber an Oncologist?

## PRIOR AUTHORIZATION REQUEST FORM

### Medicare Part D- Gilotrif (afatinib)

Phone: 800-728-7947    Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note, any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q6. If diagnosis is non-small cell lung cancer is there documentation of epidermal growth factor receptor (EGFR) exon 19 deletions?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q7. If diagnosis is metastatic non-small cell lung cancer is there documentation of epidermal growth factor receptor (EGFR) exon 21 (L858R) substitution mutations?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. If diagnosis is metastatic squamous non-small cell lung cancer, has disease progressed following platinum-based chemotherapy?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. Additional Comments	

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

- Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document